Impact of serum leptin to adiponectin ratio on regression of metabolic syndrome in high-risk individuals: The ARIRANG study

Dae Ryong Kang, Dhananjay Yadav, Sang Baek Koh, Jang Young Kim, Song Vogue Ahn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: The ratio of serum leptin to adiponectin (L/A ratio) could be used as a marker for insulin resistance. However, few prospective studies have investigated the impact of L/A ratio on improvement of metabolic components in high-risk individuals with metabolic syndrome. We examined the association between L/A ratio and the regression of metabolic syndrome in a populationbased longitudinal study. Materials and Methods: A total of 1017 subjects (431 men and 586 women) with metabolic syndrome at baseline (2005–2008) were examined and followed (2008–2011). Baseline serum levels of leptin and adiponectin were analyzed by radioimmunoassay. Area under the receiver operating characteristics curve (AUROC) analyses were used to assess the predictive ability of L/A ratio for the regression of metabolic syndrome. Results: During an average of 2.8 years of follow-up, metabolic syndrome disappeared in 142 men (32.9%) and 196 women (33.4%). After multivariable adjustment, the odds ratios (95% confidence interval) for regression of metabolic syndrome in comparisons of the lowest to the highest tertiles of L/A ratio were 1.84 (1.02–3.31) in men and 2.32 (1.37–3.91) in women. In AUROC analyses, L/A ratio had a greater predictive power than serum adiponectin for the regression of metabolic syndrome in both men (p=0.024) and women (p=0.019). Conclusion: Low L/A ratio is a predictor for the regression of metabolic syndrome. The L/A ratio could be a useful clinical marker for management of high-risk individuals with metabolic syndrome.

Original languageEnglish
Pages (from-to)339-346
Number of pages8
JournalYonsei medical journal
Volume58
Issue number2
DOIs
Publication statusPublished - 2017 Mar

Fingerprint

Adiponectin
Leptin
Serum
ROC Curve
Risk Management
Radioimmunoassay
Longitudinal Studies
Insulin Resistance
Biomarkers
Odds Ratio
Prospective Studies
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{23ecf81266ff419194f7c51592ea459c,
title = "Impact of serum leptin to adiponectin ratio on regression of metabolic syndrome in high-risk individuals: The ARIRANG study",
abstract = "Purpose: The ratio of serum leptin to adiponectin (L/A ratio) could be used as a marker for insulin resistance. However, few prospective studies have investigated the impact of L/A ratio on improvement of metabolic components in high-risk individuals with metabolic syndrome. We examined the association between L/A ratio and the regression of metabolic syndrome in a populationbased longitudinal study. Materials and Methods: A total of 1017 subjects (431 men and 586 women) with metabolic syndrome at baseline (2005–2008) were examined and followed (2008–2011). Baseline serum levels of leptin and adiponectin were analyzed by radioimmunoassay. Area under the receiver operating characteristics curve (AUROC) analyses were used to assess the predictive ability of L/A ratio for the regression of metabolic syndrome. Results: During an average of 2.8 years of follow-up, metabolic syndrome disappeared in 142 men (32.9{\%}) and 196 women (33.4{\%}). After multivariable adjustment, the odds ratios (95{\%} confidence interval) for regression of metabolic syndrome in comparisons of the lowest to the highest tertiles of L/A ratio were 1.84 (1.02–3.31) in men and 2.32 (1.37–3.91) in women. In AUROC analyses, L/A ratio had a greater predictive power than serum adiponectin for the regression of metabolic syndrome in both men (p=0.024) and women (p=0.019). Conclusion: Low L/A ratio is a predictor for the regression of metabolic syndrome. The L/A ratio could be a useful clinical marker for management of high-risk individuals with metabolic syndrome.",
author = "Kang, {Dae Ryong} and Dhananjay Yadav and Koh, {Sang Baek} and Kim, {Jang Young} and Ahn, {Song Vogue}",
year = "2017",
month = "3",
doi = "10.3349/ymj.2017.58.2.339",
language = "English",
volume = "58",
pages = "339--346",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

Impact of serum leptin to adiponectin ratio on regression of metabolic syndrome in high-risk individuals : The ARIRANG study. / Kang, Dae Ryong; Yadav, Dhananjay; Koh, Sang Baek; Kim, Jang Young; Ahn, Song Vogue.

In: Yonsei medical journal, Vol. 58, No. 2, 03.2017, p. 339-346.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of serum leptin to adiponectin ratio on regression of metabolic syndrome in high-risk individuals

T2 - The ARIRANG study

AU - Kang, Dae Ryong

AU - Yadav, Dhananjay

AU - Koh, Sang Baek

AU - Kim, Jang Young

AU - Ahn, Song Vogue

PY - 2017/3

Y1 - 2017/3

N2 - Purpose: The ratio of serum leptin to adiponectin (L/A ratio) could be used as a marker for insulin resistance. However, few prospective studies have investigated the impact of L/A ratio on improvement of metabolic components in high-risk individuals with metabolic syndrome. We examined the association between L/A ratio and the regression of metabolic syndrome in a populationbased longitudinal study. Materials and Methods: A total of 1017 subjects (431 men and 586 women) with metabolic syndrome at baseline (2005–2008) were examined and followed (2008–2011). Baseline serum levels of leptin and adiponectin were analyzed by radioimmunoassay. Area under the receiver operating characteristics curve (AUROC) analyses were used to assess the predictive ability of L/A ratio for the regression of metabolic syndrome. Results: During an average of 2.8 years of follow-up, metabolic syndrome disappeared in 142 men (32.9%) and 196 women (33.4%). After multivariable adjustment, the odds ratios (95% confidence interval) for regression of metabolic syndrome in comparisons of the lowest to the highest tertiles of L/A ratio were 1.84 (1.02–3.31) in men and 2.32 (1.37–3.91) in women. In AUROC analyses, L/A ratio had a greater predictive power than serum adiponectin for the regression of metabolic syndrome in both men (p=0.024) and women (p=0.019). Conclusion: Low L/A ratio is a predictor for the regression of metabolic syndrome. The L/A ratio could be a useful clinical marker for management of high-risk individuals with metabolic syndrome.

AB - Purpose: The ratio of serum leptin to adiponectin (L/A ratio) could be used as a marker for insulin resistance. However, few prospective studies have investigated the impact of L/A ratio on improvement of metabolic components in high-risk individuals with metabolic syndrome. We examined the association between L/A ratio and the regression of metabolic syndrome in a populationbased longitudinal study. Materials and Methods: A total of 1017 subjects (431 men and 586 women) with metabolic syndrome at baseline (2005–2008) were examined and followed (2008–2011). Baseline serum levels of leptin and adiponectin were analyzed by radioimmunoassay. Area under the receiver operating characteristics curve (AUROC) analyses were used to assess the predictive ability of L/A ratio for the regression of metabolic syndrome. Results: During an average of 2.8 years of follow-up, metabolic syndrome disappeared in 142 men (32.9%) and 196 women (33.4%). After multivariable adjustment, the odds ratios (95% confidence interval) for regression of metabolic syndrome in comparisons of the lowest to the highest tertiles of L/A ratio were 1.84 (1.02–3.31) in men and 2.32 (1.37–3.91) in women. In AUROC analyses, L/A ratio had a greater predictive power than serum adiponectin for the regression of metabolic syndrome in both men (p=0.024) and women (p=0.019). Conclusion: Low L/A ratio is a predictor for the regression of metabolic syndrome. The L/A ratio could be a useful clinical marker for management of high-risk individuals with metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85010635544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010635544&partnerID=8YFLogxK

U2 - 10.3349/ymj.2017.58.2.339

DO - 10.3349/ymj.2017.58.2.339

M3 - Article

C2 - 28120564

AN - SCOPUS:85010635544

VL - 58

SP - 339

EP - 346

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -